Jove
Visualize
Contact Us

Related Concept Videos

Drug Regulation01:25

Drug Regulation

1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

134
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
134
Pharmacovigilance01:19

Pharmacovigilance

763
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
763
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

674
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
674
Drug Nomenclature01:17

Drug Nomenclature

1.6K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.6K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.6K
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  2. Regulatory Frameworks And Filing Discrepancies In Generic Drug Approvals: A Cross-regional Study With Analysis Of Fda Anda Deficiencies.
  1. Home
  2. Regulatory Frameworks And Filing Discrepancies In Generic Drug Approvals: A Cross-regional Study With Analysis Of Fda Anda Deficiencies.

Related Experiment Video

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.3K

Regulatory frameworks and filing discrepancies in generic drug approvals: A cross-regional study with analysis of FDA

Jyoti Pawar1, Namita Hegde1, Sanjay Sharma1

  • 1Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management SVKM's NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai 400056, India.

Annales Pharmaceutiques Francaises
|March 12, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Regulatory frameworks for generic drugs vary globally. Analysis of U.S. FDA submissions (2014-2024) revealed common deficiencies in bioequivalence, chemistry, and labeling, highlighting needs for harmonization to streamline generic drug approvals.

Keywords:
Abbreviated new drug application (ANDA)Approbation du premier cycleDeficienciesDemande abrégée de drogue nouvelle (ANDA)First-cycle approvalGeneric drugsLacunesMédicaments génériquesRegulationsRéglementation

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K

Related Experiment Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.3K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K

Area of Science:

  • Pharmaceutical Regulatory Science
  • Drug Development and Approval Processes
  • Global Health Policy

Background:

  • Generic drug applications are crucial for affordable healthcare access.
  • Regulatory frameworks differ significantly across major markets like the U.S., EU, India, Japan, and China.
  • Understanding these differences and common deficiencies is key to efficient drug approval.

Purpose of the Study:

  • To analyze and compare global regulatory frameworks for generic drug applications.
  • To identify gaps and potential areas for harmonization in filing requirements.
  • To examine common deficiencies in Abbreviated New Drug Applications (ANDAs) submitted to the U.S. Food and Drug Administration (FDA) between 2014 and 2024.

Main Methods:

  • Comparative analysis of regulatory documents from FDA (U.S.), EMA (EU), CDSCO (India), PMDA (Japan), and NMPA (China).
  • Detailed review of FDA deficiency letters for ANDA submissions (2014-2024) to identify recurring issues.
  • Categorization of deficiencies across key review disciplines: bioequivalence, chemistry, and labeling.
  • Main Results:

    • A total of 172 deficiencies were identified in FDA ANDA submissions.
    • The most frequent deficiencies were in bioequivalence (35%), chemistry (34%), and labeling (31%).
    • Method validation and non-compliance with Reference Listed Drug (RLD) labeling were prominent issues.

    Conclusions:

    • Significant practical differences exist in global generic drug regulatory frameworks.
    • Harmonization of regulatory approaches could improve efficiency and standardize submissions.
    • Addressing prevalent bioequivalence and chemistry deficiencies is critical for manufacturers to accelerate generic drug registration.